Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial - Concepedia

Concepedia

Publication | Open Access

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

DOI Full Paper Access

112

Citations

17

References

2013

Year

Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras, Michael E. Menefee, Keith C. Bible, Manisha H. Shah, Ann W. Gramza, Joshua Klopper,

The Journal of Clinical Endocrinology & Metabolism

Abstract

Efatutazone and paclitaxel in combination were safe and tolerated and had biologic activity.

References

	Year	Citations

Page 1